Cencora, Inc. $COR Holdings Increased by Leuthold Group LLC

Leuthold Group LLC raised its stake in shares of Cencora, Inc. (NYSE:COR) by 9.7% during the third quarter, Holdings Channel reports. The firm owned 32,509 shares of the company’s stock after buying an additional 2,862 shares during the quarter. Leuthold Group LLC’s holdings in Cencora were worth $9,761,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in COR. BlackRock Inc. bought a new position in Cencora in the second quarter worth about $5,154,136,000. Bank of America Corp DE boosted its position in Cencora by 6.9% during the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock valued at $1,300,033,000 after acquiring an additional 267,318 shares in the last quarter. Amundi boosted its position in Cencora by 43.5% during the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock valued at $630,855,000 after acquiring an additional 676,066 shares in the last quarter. Carmignac Gestion boosted its position in Cencora by 58.7% during the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after acquiring an additional 646,112 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Cencora by 2.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,549,047 shares of the company’s stock worth $486,576,000 after acquiring an additional 35,569 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of Cencora stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president owned 19,455 shares in the company, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of COR opened at $346.16 on Tuesday. The stock has a market cap of $66.06 billion, a PE ratio of 19.32, a price-to-earnings-growth ratio of 1.84 and a beta of 0.58. The company has a debt-to-equity ratio of 3.01, a quick ratio of 0.58 and a current ratio of 0.94. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54. The firm’s 50-day simple moving average is $325.56 and its two-hundred day simple moving average is $317.25.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share for the quarter, beating analysts’ consensus estimates of $4.58 by $0.08. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The business had revenue of $88.35 billion during the quarter, compared to the consensus estimate of $87.95 billion. During the same quarter last year, the firm earned $3.84 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. Analysts anticipate that Cencora, Inc. will post 19.58 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Investors of record on Friday, November 13th will be given a dividend of $0.66 per share. This is a boost from Cencora’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, November 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio is 13.39%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on COR shares. JPMorgan Chase & Co. increased their target price on Cencora from $382.00 to $390.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Royal Bank Of Canada restated a “sector perform” rating and set a $330.00 price target on shares of Cencora in a research report on Tuesday, September 8th. Argus upped their price target on Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a research note on Tuesday, October 20th. Leerink Partners upped their price target on Cencora from $388.00 to $405.00 and gave the stock an “outperform” rating in a research note on Thursday, November 5th. Finally, Wells Fargo & Company raised their price objective on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research report on Tuesday, August 11th. Twelve equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $366.50.

Cencora Company Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally.